Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

ContraVir Pharmaceuticals ($CTRV) reported positive results  from a Phase 2a clinical trial assessing tenofovir exalidex (TXL) in patients with chronic hepatitis B virus (HBV) infection. The preliminary results showed treatment with TXL for 21 days resulted in a mean HBV viral load of 3,630 copies/mL compared to a mean viral load of 3,750 copies/mL for Gilead Sciences' Viread (tenofovir disoproxil fumarate).  There were no serious adverse events (SAEs) observed and no discontinuations due to AEs.
ContraVir stock is currently trading 25 percent up on Year to Date basis while it lost over 66 percent of its value in the past 12 months.

Immune Pharmaceuticals ($IMNP) announced inking a new deal with Pint Pharma GmnH. The firm signed a binding letter of Intent which provides for the commercialization of Ceplene (histamine dihydrochloride) in Latin America. Under the terms of the agreement, both the parties will seek an agreement extending an exclusive license to Pint for all Latin American countries including Mexico.
Pint will required to make a $4 million investment in Cytovia, which is a subsidiary of Immune Pharmaceuticals. The company stock gained over 49 percent in its previous trading session, trimming its 12 months loss to 53 percent.

 

Gilead Sciences ($GILD) announced the results from a small (n=10) open-label proof-of-concept study assessing its GS-0976 20 mg administered orally once daily for 12 weeks in patients with non-alcoholic steatohepatitis. The results showed statistically significant improvements in liver fat content and noninvasive markers of fibrosis. All adverse events were either Grade 1 or Grade 2. There were no discontinuations.
Agenus ($AGEN) announced the dosing of its first patient in a Phase ½ clinical trial assessing anti-PD-1 antibody AGEN2034 in patients with advanced solid tumors and cervical cancer. The trial will assess nearly 75 patients. The co-primary endpoints are safety (dose-limiting toxicities and maximum tolerated dose) and best overall response. The estimated study completion date is September 2019.

Teva Pharmaceutical Industries ($TEVA) announced the U.S. launch of AirDuo RespiClick (fluticasone propionate and salmeterol). The company also initiated the launch of its authorized generic for the treatment of asthma patients at least 12 years old who are inadequately controlled on an inhaled corticosteroid or whose disease severity warrants the use of an ICS/LABA combination.

Aldeyra Therapeutics ($ALDX) reported that its ADX-102 has granted an Orphan Drug status by the FDA for the treatment of Sjögren-Larsson Syndrome. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved. The company plans to conduct a Phase 3 study later this year.

 

Interpace Diagnostics ($IDXG) announced the exchange of all its  outstanding long-term $9.34M secured debt associated with the RedPath acquisition with an institutional investor at 95 cents on the dollar ($8.9M). The deal provides for Interpace to issue  a $5.3M secured convertible note and a $3.5M secured note, subsequently exchanged for a $3.5M secured convertible note.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Cantor Fitzgerald
Reiterates
Aurinia Pharmaceuticals (AUPH)
Buy
$14.00
High
BTIG Research
Initiates
Cascadian Therapeutics (CASC)
Buy

Low
Credit Suisse Group AG
Reiterates
Coherus Biosciences (CHRS)
Buy
$38.00
Low
Noble Financial
Reiterates
ContraVir Pharmaceuticals (CTRV)
Buy

Low
Raymond James Financial
Upgrades
Quest Diagnostics (DGX)
Market Perform -> Outperform

N/A
Jefferies Group LLC
Downgrades
Humana (HUM)
Buy -> Hold
$221.00
Low
Jefferies Group LLC
Reiterates
Mallinckrodt PLC (MNK)
Buy
$70.00
Low
Piper Jaffray Companies
Downgrades
Omnicell (OMCL)
Overweight -> Neutral

Low
JPMorgan Chase & Co.
Downgrades
Varex Imaging Corp (VREX)
Neutral -> Underweight

Low

Gainers (% price change)Last TradeChangeMkt CapImmunoGen, Inc.IMGN4.19+0.61 (17.04%)404.42MIRIDEX CorporationIRIX11.52+0.99 (9.40%)134.67MKindred Healthcare, Inc.KND8.95+0.68 (8.16%)811.10MSpectrum PharmaceuticalsSPPI6.97+0.49 (7.56%)568.59MRockwell Medical IncRMTI8.42+0.57 (7.26%)433.86MLosers (% price change)MEDNAX IncMD61.30-5.39 (-8.08%)5.66BNewLink Genetics CorpNLNK18.26-0.76 (-4.00%)634.25MTenet Healthcare CorpTHC14.99-0.47 (-3.04%)1.48BDigirad CorporationDRAD5.05-0.10 (-1.94%)100.89MProgenics PharmaceuticalsPGNX8.13-0.16 (-1.93%)559.18MMost Actives (dollar volume)Johnson & JohnsonJNJ121.87+0.51 (0.42%)329.16BUnitedHealth Group IncUNH171.54+2.29 (1.35%)166.08BPfizer Inc.PFE33.74+0.13 (0.39%)199.56BMerck & Co., Inc.MRK62.55-0.08 (-0.13%)172.50BHumana IncHUM214.24+1.08 (0.51%)31.12B